Astella brings in treatment for muscle disorder after gene therapy deaths; Leqembi at the FDA

Taking stock of the drug industry, from the lab to the medicine chest

June 8, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | After gene therapy deaths, Astellas brings in potentially safer treatment for muscle disorder A gene therapy for a rare muscle disorder had remarkable results, but was also tied to four boys' deaths. A successor uses a much lower dose. By Jason Mast Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA STAT Washington correspondent Rachel Cohrs joins us this week to explain Merck's lawsuit against the federal government. By Damian Garde and Meg Tirrell and Adam Feuerstein STAT+ | If AI invents a new medicine, who gets the patent? Pharma and biotech companies are increasingly using AI to discover and make medicines. Does that mean AI can be an inventor on a patent? By Brittany Trang Al Drago-Pool/Getty Images STAT+ | Top Senate Republican signals interest in site-neutral reform for hospitals A top Senate Republican signaled his interest in pursuing hospital payment reform to ensure Medicare is paying the same price for services. By Rachel Cohrs

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser